Trial · NCT06816277
Application of Local Melatonin in Peri-implantitis
NCT06816277, Not applicable, Completed, Universidad Complutense de Madrid
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Application of Local Melatonin in Peri-implantitis. Trials, record NCT06816277. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06816277
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Application of Local Melatonin in Peri-implantitis
- NCT number
- NCT06816277
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 30 participants, actual
- Lead sponsor
- Universidad Complutense de Madrid
- Conditions
- Periimplantitis
- Interventions
- Desbridamiento de periimplantitis, Aplicación de melatonina, Placebo application
- First posted
- 2025-02-10
- Last updated
- 2025-02-11
- Other registries' IDs
- eudract:2019-000828-18
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Probing depth | 60 days | The distance from the gingival margin to the bottom of the periodontal pocket was considered. The measurement was carried out in the four locations surrounding the implant, mesial, distal, lingual and vestibular. Additionally, the average of the four locations was presented. |
| Secondary | Plaque Index (Löe y Silness) | 60 days | The presence of visible bacterial plaque was considered adapted to rehabilitation using implants (Grade 0: No plaque; Grade 1: No plaque with the naked eye. There is plaque when the exploration is performed with a probe in the peri-implant area; Grade 2: There is visible bacterial plaque; Grade 3: There is visible bacterial plaque surrounding the implant, including interdental spaces. There may be stones. Adequate plaque control is considered to exist when the index results in a value ≤1. |
| Secondary | Bleeding Index (Löe y Silness) | 60 days | It was considered during the 30 seconds after probing adapted to the implant model (Grade 0: Absence of bleeding; Grade 1: A spot of blood does not appear until a few seconds after probing; Grade 2: Bleeding immediately after of probing; Grade 3: Bleeding at the slightest contact with the mucosa, extension of bleeding along the sulcus). |
| Secondary | Marginal bone loss | 60 days | The evaluation of the peri-implant-crestal bone level was performed using the ImageJ® program (NIH, Bethesda, MD, USA). From the measurement in pixels of the known length of the implant, the vertical measurement of the bone level was determined from the implant platform and perpendicular to it, to the area of turbinate bone in contact with the surface of the implant both mesial and distal. It was considered as a single measurement of the mesial and distal mean of each implant considering the clinical significance . |
| Secondary | IL-1β concentration | 60 days | Crevicular fluid samples obtained using Perio-paper strips were analyzed with the enzyme-linked immunosorbent assay (ELISA) technique. The samples were stored in sterile 13x75mm x 2 mL BD Vacutainer® tubes and were processed using the ELH-IL1B-1 Human IL-1 beta ELISA Kits 1 x 96-Wel BIONOVA CIENTIFICA S.L and HEA079HU-48T High Sensitive ELISA Kit for Interleukin 6 (IL-6) 48T BIONOVA CIENTIFICA SL for analysis of interleukin-1β and 6 at 60-90 minutes after obtaining it. The determinations were read using the ELISA reader (Ivymen System 2100-C). The standard curve of the kits was made in duplicate for IL-1β and IL-6 both in the test and in the total analysis of the samples. |
| Secondary | IL-6 concentration | 60 days | Crevicular fluid samples obtained using Perio-paper strips were analyzed with the enzyme-linked immunosorbent assay (ELISA) technique. The samples were stored in sterile 13x75mm x 2 mL BD Vacutainer® tubes and were processed using the ELH-IL1B-1 Human IL-1 beta ELISA Kits 1 x 96-Wel BIONOVA CIENTIFICA S.L and HEA079HU-48T High Sensitive ELISA Kit for Interleukin 6 (IL-6) 48T BIONOVA CIENTIFICA SL for analysis of interleukin-1β and 6 at 60-90 minutes after obtaining it. The determinations were read using the ELISA reader (Ivymen System 2100-C). The standard curve of the kits was made in duplicate for IL-1β and IL-6 both in the test and in the total analysis of the samples. |
| Secondary | Microbiological count | 60 days | A Colon Forming Unit (CFU) count was performed on the crevicular fluid samples obtained using sterile paper points. They were transferred into a vial of reduced transport liquid with 1.0 mL of RTF transport medium to preserve the anaerobiosis of the samples for 24 hours and quantify the sample volume. The samples were immediately cultured on blood agar medium and the peri-implantopathogenic, periodontopathogenic and candida species were identified. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06816277
GET https://conductscience.org/api/trials/v1/NCT06816277/registered